Clinical trials: Rectum Neoplasm
Rectal Cancer
TaTME Versus Open Intersphincteric Resection After Neoadjuvant Concurrent Chemoradiotherapy.
The two surgical options for lower 1/3 rectal cancer is APR and sphincter sparing procedures. Intersphincteric resection is procedure to treat very low rectal cancer within 2 cm from the dentate line to avoid permanent…
- Trial name
- TaTME (NCT01836926)
- Testing
- Open intersphincteric resection, transanal minimally invasive intersphincteric resection
- Where
- 2 sites in Egypt
- Volunteers
- 110 people
- Sponsor
- Osama Mohammad Ali ElDamshety
Rectal Cancer
Next Generation STAR-TREC (NG-ST) - Organ Preservation in Early Rectal Cancer
This study evaluates whether mesorectal chemoradiotherapy with a limited radiation target volume can achieve a sustained clinical complete response in patients with early-stage rectal cancer, allowing surgery to be safely…
- Trial name
- NG-ST (NCT07483060)
- Testing
- Capecitabine + Radiotherapy, Total Mesorectal Excision (TME)
- Volunteers
- 90 people
- Sponsor
- Vastra Gotaland Region
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum
Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer
This phase II trial studies how well giving aflibercept together with combination chemotherapy works in treating patients with previously untreated colon or rectal cancer that is metastatic or locally advanced and cannot be…
- Conditions
- Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum
- Trial name
- NCT01652196
- Testing
- aflibercept, oxaliplatin, leucovorin
- Where
- 6 sites in United States
- Volunteers
- 56 people
- Sponsor
- John Hays
Rectal Cancer, Left Colic Artery Stenosis (Diagnosis)
Robotic-Assisted or Laparoscopic Radical Resection for Rectal Cancer With or Without Left Colic Artery Preservation
Brief Summary Background The preservation of the left colic artery (LCA) during rectal cancer resection remains a topic of controversy, and there is a notable absence of robust evidence regarding the outcomes associated with LCA…
- Conditions
- Rectal Cancer, Left Colic Artery Stenosis (Diagnosis), Robotic Assisted Laparoscopic Surgery
- Trial name
- NCT06376227
- Testing
- with or without Left Colic Artery Preservation
- Where
- China
- Volunteers
- 1,164 people
- Sponsor
- Northern Jiangsu People's Hospital
Neoplasms, Colorectal Neoplasms
Study of PRoliferation and Apoptosis in Rectal Cancer, Predictive & Prognostic biOmarkers: Histopathology and Imaging
This study tests biopsy and tissue from patients who have been treated for primary rectal cancer at the Royal Marsden Hospital between 2011 and 2013, who have an mrTRG score at post-chemoradiotherapy MRI.
- Conditions
- Neoplasms, Colorectal Neoplasms, Rectal Diseases, Gastrointestinal Neoplasms
- Trial name
- SOPRANO (NCT02486094)
- Where
- United Kingdom
- Volunteers
- 148 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Localized Malignant Solid Neoplasm, Anal Cancer
Distance-Based Exercise to Preserve Function and Prevent Disability
This clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and allow patients to exercise in their own home.
- Conditions
- Localized Malignant Solid Neoplasm, Anal Cancer, Bladder (Urothelial, Transitional Cell) Cancer, Breast Cancer
- Trial name
- DEFEND (NCT07059884)
- Testing
- Exercise intervention, Telemedicine, Aerobic Exercise Intervention
- Where
- 23 sites in United States
- Volunteers
- 104 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Colorectal Cancer, Colon Cancer
Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)
To measure the level of circulating tumor DNA (ctDNA) in the blood of colorectal cancer patients after 6 months of receiving therapy with regorafenib and XmAb20717 (also known as vudalimab).
- Conditions
- Colorectal Cancer, Colon Cancer, Rectum Cancer
- Trial name
- NCT05900648
- Testing
- Regorafenib, XmAb20717
- Sponsor
- M.D. Anderson Cancer Center
Rectal Cancer
A Study of PEP503(Radio-enhancer) With Radiotherapy and Chemotherapy for Patients With Rectal Cancer
This phase Ib/II study is a prospective, open-label, single arm, nonrandomized study of PEP503(radio-enhancer). There are 2 portions in this study.
- Trial name
- NCT02465593
- Testing
- PEP503, 5-fluorouracil, capecitabine
- Where
- Taiwan
- Volunteers
- 32 people
- Sponsor
- PharmaEngine
Rectal Cancer
Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer
The standard treatment for rectal cancer is to receive the chemotherapeutic drug 5-fluorouracil (5-FU) with radiation therapy before having surgery to remove the rectal cancer. This is known as neoadjuvant chemoradiotherapy.
- Trial name
- NCT00611858
- Testing
- Cetuximab, 5-Fluorouracil, Radiation
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- Dana-Farber Cancer Institute
Anal Squamous Cell Cancer
Chemoradiotherapy and Anti-PD-1 Antibody in Anal Squamous Cell Cancer：Chase
Squamous cell carcinoma (SCC) of the anus is a rare malignancy. For localized anal squamous cell carcinoma , definitive chemoradiotherapy is the standard treatment.
- Trial name
- Chase (NCT07555678)
- Testing
- PD-1 Inhibitor + Chemotherapy
- Where
- China
- Volunteers
- 241 people
- Sponsor
- Fudan University
Colon Rectal Cancer Duke Stage Stageval
A Trial of Pre-Operative Chemoradiotherapy Using Capecitabine, Radiation & Cetuximab, in Rectal Cancer
A Pilot Trial of Pre-Operative Chemoradiotherapy Using Capecitabine (Xelodaâ), External Beam Radiation and Cetuximab (Erbitux®) Followed by Definitive Surgery in Patients With Localized (Non-Metastatic) Rectal Cancer
- Trial name
- NCT01310985
- Testing
- Capecitabine (Xelodaâ), XRT & Cetuximab (Erbitux®)
- Where
- Saudi Arabia
- Volunteers
- 15 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
HPV-Related Carcinoma, HPV Infection
Determining the Frequency of Occurrence and Defining the Most Appropriate Screening Test for Anal Intraepithelial Neoplasia (AIN) in Patients With Human Papillomavirus (HPV) Related Gynecological Diseases.
The primary aim of the study is to determine the total risk of AIN in group of HPV-RGD survivors and additionally to establish an exact risk for each of HPV-related gynecological precancers/cancers.
- Trial name
- NCT06574087
- Testing
- hrHPV test and cytology
- Where
- Poland
- Volunteers
- 248 people, healthy volunteers welcome
- Sponsor
- PCK Marine Hospital in Gdynia
Colo-rectal Cancer, Colon Cancer
Delayed Colorectal Cancer Care During Coronavirus Disease (COVID-19) Pandemic (DECOR-19)
To understand and analyse the global impact of COVID-19 on outpatient services, inpatient care, elective surgery, and perioperative colorectal cancer care, a DElayed COloRectal cancer surgery (DECOR-19) survey was conducted in…
- Conditions
- Colo-rectal Cancer, Colon Cancer, Rectal Cancer, Oncology
- Trial name
- DECOR-19 (NCT04488549)
- Testing
- Survey
- Where
- Italy
- Volunteers
- 1,051 people
- Sponsor
- Treviso Regional Hospital
Rectal Cancer
A Prospective Phase II Study of Individualized Neoadjuvant Chemoradiotherapy for Rectal Cancer Based on Recurrence Risk
A Prospective Phase II Study of Individualized Neoadjuvant Chemoradiotherapy for Rectal Cancer Based on Recurrence Risk
- Trial name
- NCT04664504
- Testing
- Concurrent Chemoradiotherapy Radiotherapy, Short-course Radiotherapy, Local dose increase of Short-course Radiotherapy
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Jing Jin, M.D.
Esophagus Cancer, Stomach Cancer
Effects of S-1 and Capecitabine on Coronary Artery Blood Flow
Fluoropyrimidine chemotherapy agents , such as 5-fluorouracil and capecitabine, are occasionally associated with cardiac toxicity.
- Conditions
- Esophagus Cancer, Stomach Cancer, Small Bowel Cancer, Colon Cancer
- Trial name
- FluoHeart (NCT02216149)
- Testing
- S-1, Capecitabine, Oxaliplatin
- Where
- Finland
- Volunteers
- 20 people
- Sponsor
- Heikki Joensuu
Rectal Cancer
Multicenter Study on Preservation Versus Excision of Denonvilliers Fascia in L-PANP Surgery
TME (Total mesorectum excision) is the golden standard of radical resection for mid-low rectal cancer. However, the damage of pelvic autonomic nerve following with TME principle will lead to high incidence of urinary and sexual…
- Trial name
- NCT02435758
- Testing
- Preservation of Denonvilliers Fascia during L-PANP surgery
- Where
- China
- Volunteers
- 262 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Cancer
Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer
RATIONALE: Learning about the relationship between platinum levels in the blood and neurotoxicity in patients receiving oxaliplatin may help plan treatment and may help patients live more comfortably.
- Trial name
- NCT00274885
- Testing
- oxaliplatin, management of therapy complications
- Where
- 6 sites in France
- Volunteers
- 58 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Stage II Rectal Cancer, Stage III Rectal Cancer
Quicksilver II Pilot Study
This pilot study is being done to answer the following question: Will patients with margin-clear Stage 2 or 3 rectal cancer who don't require a colostomy agree to be randomized to 'surgery only' or 'chemotherapy and then…
- Trial name
- NCT07688135
- Testing
- Direct-to-surgery (i.e., no neoadjuvant chemotherapy), Control Group
- Volunteers
- 18 people
- Sponsor
- Mount Sinai Hospital, Canada
Rectal Cancer
Hydralazine as a Demethylating Agent in Rectal Cancer
Clinically feasible dose of Hydralazine for ~ 3 months, by virtue of its demethylating effect, will: 1. Result in re-expression of epigenetically silenced TSGs in rectal cancer specimens. 2.
- Trial name
- NCT00575640
- Testing
- Hydralazine
- Sponsor
- University of Arkansas
Rectal Cancer
Evaluate Efficacy, Morbidity and Functional Outcome of Endoscopic TranAnal Proctectomy vs Standard Transabdominal Laparoscopic Proctectomy for Rectal Cancer
Standard surgical treatment of mid and low rectal cancer is total mesorectal excision (TME). Originally performed by open surgery, TME demonstrated improved local control and reduced urogenital morbidity.
- Trial name
- ETAP (NCT02584985)
- Testing
- ETAP, Standard Transabdominal Laparoscopic Proctectomy
- Where
- France
- Volunteers
- 226 people
- Sponsor
- Institut Paoli-Calmettes
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.